IntelGenX, a leading drug delivery company focused on the development and manufacturing of pharmaceutical films, said that the first patient has been dosed in the resumed phase 2a clinical trials of montelukast for mild to moderate Alzheimer’s Disease. The BUENA (NCT03402503) trials had been suspended in late 2020 due to COVID-19 pandemic. Montelukast is commonly used for the treatment of asthma and seasonal allergies  and the company said that it is working on repurposing the therapy for treating neurodegenerative diseases by reformulating the medication into an oral film with the use of its proprietary VersaFilm technology. The company expressed hopes for the topline results from the trial and that it would help establish complete insight into the safety, feasibility, tolerability and efficacy of Montelukast VersaFilm.